The clinical and demographic characteristics of patients undergoing transcatheter aortic valve implantation (TAVI) pose unique challenges for coronary computed tomography (CT) imaging, as this patient population is mainly composed of elderly, frail individuals with severe aortic stenosis, multiple comorbidities, high prevalence of heavily calcified coronary artery disease (CAD) and revascularized coronary arteries. Such vulnerable patients could benefit from a more precise assessment and characterization of their CAD with ultra-high resolution (UHR) photon-counting detector (PCD) CT that would potentially avoid the need for pre-implantation invasive coronary angiography (ICA). This international multicenter prospective registry study aims to investigate the feasibility and diagnostic accuracy of PCD-CT in the assessment of CAD in the high-risk population of patients undergoing TAVI, as compared to ICA.
Study Type
OBSERVATIONAL
Enrollment
1,000
Clinically indicated Ultra-High Resolution Photon-Counting Detector Coronary Computed Tomography Angiography (UHR PCD-CT CCTA) for the pre-procedural evaluation of patients scheduled to undergo transcatheter aortic valve implantation.
Medical University of South Carolina
Charleston, South Carolina, United States
RECRUITINGAlbert-Ludwigs-Universität Freiburg
Freiburg im Breisgau, Germany
NOT_YET_RECRUITINGUniversity Medical Center Mainz
Mainz, Germany
RECRUITINGUniversitätsklinikum Tübingen
Tübingen, Germany
NOT_YET_RECRUITINGSemmelweis University
Budapest, Hungary
RECRUITINGMaastricht University
Maastricht, Netherlands
NOT_YET_RECRUITINGUniversity Hospital of Zürich
Zurich, Switzerland
NOT_YET_RECRUITINGDiagnostic Accuracy of Ultra-High Resolution Photon-Counting Detector Coronary Computed Tomography Angiography (UHR PCD-CT CCTA)
Assessment of the diagnostic accuracy (sensitivity, specificity, PPV, NPV) of UHR PCD-CT coronary angiography as compared to invasive coronary angiography (ICA) within three months of PCD-CT
Time frame: through study completion, an average of 2 years
Image Noise Analysis Across Reconstruction Parameters
Quantitative assessment of image noise (measured in HU) in CT images reconstructed with varying parameters, including reconstruction kernel type, quantum iterative reconstruction (QIR) levels, and slice thickness.
Time frame: through study completion, an average of 2 years
Correlation of Image Noise and Body Mass Index
Correlation of image noise (measured in HU) and body mass index (kg/m2) across different image reconstruction parameters, including kernel type, quantum iterative reconstruction (QIR) level, and slice thickness.
Time frame: through study completion, an average of 2 years
Correlation of Image Noise and Heart Rate
Correlation of image noise (measured in HU) and heart rate (bpm) across different image reconstruction parameters, including kernel type, quantum iterative reconstruction (QIR) level, and slice thickness.
Time frame: through study completion, an average of 2 years
Contrast-to-Noise Ratio (CNR) Analysis Across Reconstruction Parameters
Quantitative assessment of contrast-to-noise ratio (unitless) in CT images reconstructed with varying parameters, including reconstruction kernel type, quantum iterative reconstruction (QIR) levels, and slice thickness.
Time frame: through study completion, an average of 2 years
Vessel Sharpness Analysis Across Reconstruction Parameters
Quantitative assessment of vessel sharpness (measured in 1/mm) in CT images reconstructed with varying parameters, including reconstruction kernel type, quantum iterative reconstruction (QIR) levels, and slice thickness.
Time frame: through study completion, an average of 2 years
Blooming Analysis Across Reconstruction Parameters
Quantitative assessment of blooming (percentage) in CT images reconstructed with varying parameters, including reconstruction kernel type, quantum iterative reconstruction (QIR) levels, and slice thickness.
Time frame: through study completion, an average of 2 years
Subjective Image Quality Analysis
Overall image quality, image noise and vessel sharpness assessed on a 4-point Likert scale (1 = non-diagnostic, 4 = excellent) by 2 blinded readers/site. Comparison of image quality between reconstructions with varying parameters, including reconstruction kernel type, quantum iterative reconstruction (QIR) levels, and slice thickness.
Time frame: through study completion, an average of 2 years
Correlation of Quantitative Coronary Artery Disease Assessment
Correlation and agreement of percent diameter stenosis (PDS) measured on UHR PCD-CT dataset and quantitative coronary angiography (QCA).
Time frame: through study completion, an average of 2 years
Correlation of Quantitative In-Stent Restenosis Assessment
Correlation and agreement of quantitative in-stent restenosis (ISR) measured on UHR PCD-CT dataset and quantitative coronary angiography (QCA).
Time frame: through study completion, an average of 2 years
Correlation of Fractional Flow Reserve Measurement
Correlation and agreement of CT-based fractional flow reserve (FFR-CT) measured on UHR PCD-CT dataset and invasive fractional flow reserve.
Time frame: through study completion, an average of 2 years
Quantitative Assessment of Plaque Composition
Measure the volume of plaque components (in mm3) on UHR PCD-CT datasets across different image reconstruction parameters, including kernel type and quantum iterative reconstruction (QIR) level.
Time frame: through study completion, an average of 2 years
Correlation of Plaque Composition
Correlation and agreement of plaque composition assessment from UHR PCD-CT dataset and intracoronary techniques such as optical coherence tomography (OCT) in patients who had both tests done.
Time frame: through study completion, an average of 2 years
Quantitative Assessment of Extracellular Volume Fraction
Quantitative analysis of the extracellular volume (ECV) fraction measured on PCD-CT dataset.
Time frame: through study completion, an average of 2 years
Analysis of Structured Coronary Artery Disease Reporting in UHR PCD-CT
Analysis of coronary artery disease classification according to the Coronary Artery Disease-Reporting and Data System (CAD-RADS 2.0).
Time frame: through study completion, an average of 2 years
Correlation of Quantitative UHR PCD-CT CCTA Parameters with Ischemia Imaging Tests
Correlation of quantitative UHR PCD-CT CCTA parameters with the results of additional imaging ischemia tests in patients who had both PCD-CT CCTA and one of the following tests done: stress echocardiography, stress single photon emission computed tomography (SPECT), stress positron emission tomography (PET), and stress magnetic resonance imaging (MRI).
Time frame: through study completion, an average of 2 years
Correlation of Quantitative UHR PCD-CT CCTA Parameters with Other Imaging Tests
Correlation of quantitative UHR PCD-CT CCTA parameters with the results of additional imaging tests in patients who had both PCD-CCTA and one of the following tests done: transthoracic echocardiography, transesophageal echocardiography, cardiac MRI.
Time frame: through study completion, an average of 2 years
Correlation Between PCAT Attenuation and CT-derieved or Clinical Parameters
To assess the correlation between pericoronary adipose tissue (PCAT) attenuation (measured in HU on UHR PCD-CT CCTA data) and (1) anatomical severity of CAD (percent diameter stenosis), (2) functional severity of disease (FFR-CT), (3) plaque composition and (4) clinical outcome.
Time frame: from inclusion up to a maximum follow-up period of 5 years
Correlation Between EAT Attenuation and CT-derieved or Clinical Parameters
To assess the correlation between epicardial adipose tissue (EAT) attenuation (measured in HU on UHR PCD-CT CCTA data) and (1) anatomical severity of CAD (percent diameter stenosis), (2) functional severity of disease (FFR-CT), (3) plaque composition and (4) clinical outcome.
Time frame: from inclusion up to a maximum follow-up period of 5 years
Lung Water Density Quantification
Measurement of lung water density by virtual non-contrast CT and iodine mapping CT, compared to non-contrast CT.
Time frame: through study completion, an average of 2 years
Assessment of Whole Body Extracellular Volume
Assessment of whole body extracellular volume (ECV) in patients undergoing TAVI compared to healthy volunteer controls scanned in a separate study.
Time frame: through study completion, an average of 2 years
Major Adverse Cardiac Events
Composite endpoint of major adverse cardiovascular event (MACE); defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, stroke.
Time frame: from inclusion up to a maximum follow-up period of 5 years
Extended Major Adverse Cardiovascular Events
Composite endpoint of major adverse cardiovascular event (MACE); defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, stroke, unstable angina, or heart failure admission
Time frame: from inclusion up to a maximum follow-up period of 5 years
Prosthesis Function Evaluation
Subjective analysis of prosthesis function using UHR and spectral PCD-CT data to detect pathologies e.g. hypoattenuating leaflet thickening (HALT).
Time frame: from inclusion up to a maximum follow-up period of 5 years
Cost-effectiveness
Costs of PCD-CT and complications compared with costs of ICA and complications.
Time frame: from inclusion up to a maximum follow-up period of 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.